Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker REPL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTL… NCT06264180 · Advanced Melanoma Vusolimogene Oderparepvec, Nivolumab | REPL Replimune, Inc. | Phase 3 | Recruiting | 400 | Sep 30, 2030 | Registry ↗ |
| Apr 22, 2026 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Ad… NCT04349436 · Merkel Cell Carcinoma, Basal Cell Carcinoma RP1, intra-tumoral injection, oncolytic virus | REPL Replimune, Inc. | Phase 1/2 | Active, not recruiting | 69 | Jul 2029 | Registry ↗ |
| Apr 2, 2026 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Niv… NCT06581406 · Metastatic Uveal Melanoma RP2, Ipilimumab | REPL Replimune, Inc. | Phase 2/3 | Recruiting | 280 | Jan 2030 | Registry ↗ |
| Apr 2, 2026 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastati… NCT05733598 · Hepatocellular Carcinoma, Biliary Tract Cancer RP2, Bevacizumab | REPL Replimune, Inc. | Phase 2 | Recruiting | 60 | Dec 1, 2027 | Registry ↗ |
| Feb 27, 2026 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours NCT04735978 · Advanced Solid Tumor RP3, Nivolumab | REPL Replimune, Inc. | Phase 1 | Active, not recruiting | 123 | Nov 30, 2026 | Registry ↗ |
| Feb 27, 2026 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors NCT04336241 · Cancer RP2, nivolumab | REPL Replimune, Inc. | Phase 1 | Active, not recruiting | 36 | Oct 31, 2026 | Registry ↗ |
| Feb 13, 2026 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) NCT03767348 · Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instabil… RP1, nivolumab | REPL Replimune, Inc. | Phase 2 | Active, not recruiting | 340 | Jun 2028 | Registry ↗ |
| Feb 2, 2026 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC NCT05733611 · Refractory Metastatic Colorectal Cancer, pMMR RP2, RP3 | REPL Replimune, Inc. | Phase 2 | Terminated | 5 | Aug 18, 2025 | Registry ↗ |
| Jan 12, 2026 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348 · Melanoma, Metastatic Melanoma Observational study with no interventions | REPL Replimune, Inc. | — | Recruiting | 50 | Dec 2030 | Registry ↗ |
| Dec 18, 2025 | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Mel… NCT06590480 · Advanced Melanoma RP1, Nivolumab | REPL Replimune, Inc. | — | No longer available | — | — | Registry ↗ |
| Mar 11, 2025 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanc… NCT05743270 · Squamous Cell Carcinoma of Head and Neck, Locally Advanced… RP3, CCRT(concurrent chemoradiation therapy) | REPL Replimune, Inc. | Phase 2 | Withdrawn | 0 | Mar 1, 2026 | Registry ↗ |
| Jan 27, 2025 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer NCT04050436 · Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squam… Cemiplimab, RP1 | REPL Replimune, Inc. | Phase 2 | Active, not recruiting | 231 | Sep 2025 | Registry ↗ |
12 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:19 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances